Navigation Links
Isis Pharmaceuticals Earns $1 Million from GSK for Advancing ISIS-TTR Rx

CARLSBAD, Calif., July 16, 2014 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announced today that it has earned a $1 million milestone payment from GlaxoSmithKline (GSK) related to the advancement of the Phase 2/3 study of ISIS-TTRRx in patients with familial amyloid polyneuropathy (FAP). 

ISIS-TTRRx is an antisense drug in development with GSK for the treatment of transthyretin amyloidosis, a severe and rare genetic disease characterized by progressive dysfunction of peripheral nerve and/or heart tissues.  Including this milestone payment, Isis has generated $27 million in upfront and milestone payments for advancing ISIS-TTRRx.  This $1 million milestone payment is the fifth of the nearly $58 million in milestone payments Isis is eligible to earn as the Phase 2/3 study progresses.  In addition, if GSK elects to exercise its option to exclusively license the ISIS-TTRRx program, Isis is eligible to receive a license fee, regulatory and sales milestone payments and double-digit royalties on sales of ISIS-TTRRx.

The Phase 2/3 study of ISIS-TTRRx is a randomized, double-blind, placebo-controlled, international study designed to support an application for marketing approval of ISIS-TTRRx in patients with FAP.  The fifteen month study will measure the effects of ISIS-TTRRx on neurological dysfunction and on quality-of-life.  ISIS-TTRRx is an investigational drug that is designed to inhibit the production of all forms of TTR, and to treat all types of transthyretin-related amyloidosis.  For further study information, please visit and search for the identifier number NCT01737398.

Isis is exploiting its leadership position in antisense technology to discover and develop novel drugs for its product pipeline and for its partners.  Isis' broad pipeline consists of 32 drugs to treat a wide variety of diseases with an emphasis on cardiovascular, metabolic, severe and rare diseases, including neurological disorders, and cancer.  Isis' partner, Genzyme, is commercializing Isis' lead product, KYNAMRO®, in the United States and other countries for the treatment of patients with homozygous FH.  Isis' patents provide strong and extensive protection for its drugs and technology.  Additional information about Isis is available at

This press release includes forward-looking statements regarding Isis' strategic alliance with GSK, and the development, activity, therapeutic and commercial potential and safety of ISIS-TTRRx.  Any statement describing Isis' goals, expectations, financial or other projections, intentions or beliefs is a forward-looking statement and should be considered an at-risk statement.  Such statements are subject to certain risks and uncertainties, particularly those inherent in the process of discovering, developing and commercializing drugs that are safe and effective for use as human therapeutics, and in the endeavor of building a business around such drugs.  Isis' forward-looking statements also involve assumptions that, if they never materialize or prove correct, could cause its results to differ materially from those expressed or implied by such forward-looking statements.  Although Isis' forward-looking statements reflect the good faith judgment of its management, these statements are based only on facts and factors currently known by Isis.  As a result, you are cautioned not to rely on these forward-looking statements.  These and other risks concerning Isis' programs are described in additional detail in Isis' annual report on Form 10-K for the year ended December 31, 2013, and its most recent quarterly report on Form 10-Q, which are on file with the SEC. Copies of these and other documents are available from the Company.

In this press release, unless the context requires otherwise, "Isis," "Company," "we," "our," and "us" refers to Isis Pharmaceuticals and its subsidiaries.

Isis Pharmaceuticals® is a registered trademark of Isis Pharmaceuticals, Inc.  Regulus Therapeutics™ is a trademark of Regulus Therapeutics Inc.  KYNAMRO® is a registered trademark of Genzyme Corporation.

Logo -

SOURCE Isis Pharmaceuticals, Inc.
Copyright©2014 PR Newswire.
All rights reserved

Related medicine technology :

1. Savient Pharmaceuticals to Hold First Quarter 2012 Financial Results Conference Call on Wednesday, May 9, 2012
2. Auxilium Pharmaceuticals to Present at the Deutsche Bank 37th Annual Healthcare Conference
3. Nouveau Life Pharmaceuticals (HRID) Contracts with U.S. Manufacturer to Produce New Female Supplement
4. BioElectronics Survey Indicates a Five-Fold Superior Pain Relief Compared to OTC Pharmaceuticals
5. Icahn Issues Statement Regarding Amylin Pharmaceuticals
6. Almost 50 Percent of the Glaucoma Patient Population Remains Untreated, Signifying a Vast Market for Glaucoma Pharmaceuticals, Finds Frost & Sullivan
7. Omthera Pharmaceuticals Announces Positive Top-Line Results from Phase 3 EVOLVE Study
8. Onyx Pharmaceuticals Announces FDA Advisory Committee to Review Carfilzomib for the Treatment of Patients with Relapsed and Refractory Multiple Myeloma
9. Jazz Pharmaceuticals Announces First Quarter 2012 Financial Results Conference Call On May 8, 2012
10. Inovio Pharmaceuticals Granted U.S. Patent Protection for Synthetic Vaccine for Cervical Dysplasia and Cancer
11. Avanir Pharmaceuticals To Present at Three Conferences In May
Post Your Comments:
(Date:10/13/2015)... , October 13, 2015 ... World Thrombosis Day Interactive Infographic   --> ... World Thrombosis Day  to promote vital global awareness ... and symptoms. Thrombosis is the formation of potentially ... - resulting in venous thromboembolism (VTE) - or the ...
(Date:10/12/2015)... Given the intricacy of the anatomy and physiology of ... drug effectively to a specific ocular site. Several barriers have ... include dilution of a drug by tears, clearance of a ... issues with respect to the cornea, sclera and choroid. Approximately ... due to the aforementioned barriers. --> Given ...
(Date:10/12/2015)... 12, 2015  The Pharmacy Compounding Accreditation Board ... Pharmacy in Costa Mesa , ... the pharmacy,s commitment to meeting and/or exceeding national ... --> --> ... --> --> Harbor Compounding ...
Breaking Medicine Technology:
(Date:10/13/2015)... ... ... Symposium Chairman, Dr. Rod J. Rohrich is pleased to announce that registration ... 2nd and 3rd, 2016. The annual meeting, along with the Dallas Rhinoplasty ... the world. , Key topics at this year's event will include discussions on efficacy ...
(Date:10/13/2015)... ... October 13, 2015 , ... e-con Systems Inc., a ... announced See3CAM_CU40, the industry’s first RGB-IR pixel format camera with a USB ... member of e-con’s See3CAM family of UVC USB 3.0 cameras, is based on the ...
(Date:10/13/2015)... ... October 13, 2015 , ... Altec ... their Title Sponsorship of Synergy 2015. The annual WennSoft KEY2ACT user conference will ... Ranch and will unite customers, partners, WennSoft team members and sponsors to facilitate ...
(Date:10/13/2015)... ... October 13, 2015 , ... Tempe Dental Care, a leading Tempe dentists’ office, ... IV sedation dentistry for more than 5 years. A leading cause of emergency ... painful if treatment is not timely. , Sedation dentistry provides an ...
(Date:10/13/2015)... ... October 13, 2015 , ... Breathing is ... do not breathe correctly. According to T’ai Chi (also spelled “Taiji”) and Qigong ... breathe correctly, in concert with the 7,000 year old tradition they teach, can ...
Breaking Medicine News(10 mins):